{"id":"adrenaline-promethazine-hydrocortisone","safety":{"commonSideEffects":[{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Anxiety"},{"rate":null,"effect":"Drowsiness (from promethazine)"},{"rate":null,"effect":"Hyperglycemia (from hydrocortisone)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adrenaline acts as a sympathomimetic agent, increasing heart rate and blood pressure through α and β-adrenergic receptor activation. Promethazine is a first-generation antihistamine that blocks H1 receptors and has anticholinergic properties, reducing histamine-mediated reactions and providing sedation. Hydrocortisone is a glucocorticoid that suppresses inflammatory and immune responses by inhibiting phospholipase A2 and reducing cytokine production.","oneSentence":"This combination uses adrenaline to stimulate adrenergic receptors for rapid cardiovascular support, promethazine to block histamine and provide sedation, and hydrocortisone to suppress inflammation and immune response.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:19:54.351Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anaphylaxis (acute allergic reaction)"},{"name":"Severe allergic reactions with cardiovascular compromise"},{"name":"Acute inflammatory conditions with hemodynamic instability"}]},"trialDetails":[{"nctId":"NCT06078696","phase":"PHASE1, PHASE2","title":"Siplizumab for Sickle Cell Disease Transplant","status":"TERMINATED","sponsor":"Columbia University","startDate":"2023-09-28","conditions":"Anemia, Sickle Cell","enrollment":1},{"nctId":"NCT03913559","phase":"PHASE2","title":"Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-05-14","conditions":"Acute Lymphoblastic Leukemia","enrollment":5},{"nctId":"NCT04456439","phase":"","title":"Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)","status":"NO_LONGER_AVAILABLE","sponsor":"Mesoblast International Sàrl","startDate":"","conditions":"Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)","enrollment":""},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT00185692","phase":"PHASE2","title":"Allogeneic Transplantation From Related Haploidentical Donors","status":"COMPLETED","sponsor":"Stanford University","startDate":"2000-08","conditions":"Blood Cancer, Leukemia, Graft Versus Host Disease","enrollment":16},{"nctId":"NCT00482053","phase":"PHASE2","title":"Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT","status":"TERMINATED","sponsor":"Stanford University","startDate":"2006-10","conditions":"Lymphoma, B-cell, Lymphoma, Non-Hodgkin, Diffuse Large B-cell Lymphoma (DLBCL)","enrollment":3},{"nctId":"NCT00186628","phase":"PHASE2","title":"Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD","status":"COMPLETED","sponsor":"Stanford University","startDate":"2005-06","conditions":"Leukemia, Mast-Cell, Mantle-cell Lymphoma","enrollment":36},{"nctId":"NCT00899847","phase":"PHASE2","title":"Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-05","conditions":"Transplantation, Homologous, Transplantation, Autologous, Multiple Myeloma","enrollment":9},{"nctId":"NCT00270777","phase":"PHASE4","title":"Improving Safety of Antivenom in People Bitten by Snakes","status":"COMPLETED","sponsor":"University of Kelaniya","startDate":"2005-03","conditions":"Snake Bites","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"adrenaline, promethazine, hydrocortisone","genericName":"adrenaline, promethazine, hydrocortisone","companyName":"University of Kelaniya","companyId":"university-of-kelaniya","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses adrenaline to stimulate adrenergic receptors for rapid cardiovascular support, promethazine to block histamine and provide sedation, and hydrocortisone to suppress inflammation and immune response. Used for Anaphylaxis (acute allergic reaction), Severe allergic reactions with cardiovascular compromise, Acute inflammatory conditions with hemodynamic instability.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}